Literature DB >> 7870589

Stability of adriamycin-induced DNA adducts and interstrand crosslinks.

A van Rosmalen1, C Cullinane, S M Cutts, D R Phillips.   

Abstract

The stability of adriamycin-induced DNA adducts and interstrand crosslinks was measured at 37 degrees C by three independent procedures. The loss of [14C]-labelled adducts was described by two first-order decays with half-lives of 7.4 h (60% amplitude) and 39 h (40%). The loss of the drug chromophore also exhibited a biphasic character, with half-lives of 6 h (65%) and approximately 150 h (35%). The decay of transcriptional blockages at an isolated, apparent interstrand GpC crosslinking site was described by two first-order processes, with half-lives of 3 h (65%) and 40 h (35%), whereas the decay of transcriptional blockages at an isolated guanine residue (apparent site of monoadduct) was completely described by a first-order decay with a half-life of 5.3 h. The loss of interstrand crosslinks was measured using a gel electrophoresis assay, and the decay was characterised by a single first-order process with a half-life of 4.7 h. Collectively, these values serve to define a model of the interstrand crosslink with unstable sites of attachment at both ends of the crosslink, with half-lives at either end being approximately 5 and 40 h. The adducts exhibited increasing lability with increasing pH, and were particularly unstable at pH 12, with a half-life of approximately 0.5 h. The adducts were also heat labile, with an overall melting temperature of 67 degrees C (10 min exposure) and this was also the thermal lability measured at three individual adduct sites probed by lambda exonuclease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7870589      PMCID: PMC306628          DOI: 10.1093/nar/23.1.42

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  32 in total

Review 1.  Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling.

Authors:  H Kappus
Journal:  Biochem Pharmacol       Date:  1986-01-01       Impact factor: 5.858

2.  Binding of [14C]-adriamycin to cellular macromolecules in vivo.

Authors:  B K Sinha; R H Sik
Journal:  Biochem Pharmacol       Date:  1980-06-15       Impact factor: 5.858

3.  One-electron reduction of adriamycin: properties of the semiquinone.

Authors:  E J Land; T Mukherjee; A J Swallow; J M Bruce
Journal:  Arch Biochem Biophys       Date:  1983-08       Impact factor: 4.013

Review 4.  On the mechanism of reductive activation in the mode of action of some anticancer drugs.

Authors:  V Favaudon
Journal:  Biochimie       Date:  1982-07       Impact factor: 4.079

5.  Transfer of ferritin-bound iron to adriamycin.

Authors:  E J Demant
Journal:  FEBS Lett       Date:  1984-10-15       Impact factor: 4.124

6.  Formation of adriamycin--DNA adducts in vitro.

Authors:  C Cullinane; S M Cutts; A van Rosmalen; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

7.  Enzymatic activation and binding of adriamycin to nuclear DNA.

Authors:  B K Sinha; M A Trush; K A Kennedy; E G Mimnaugh
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

8.  Anthracycline antibiotic reduction by spinach ferredoxin-NADP+ reductase and ferredoxin.

Authors:  J Fisher; B R Abdella; K E McLane
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

9.  7-Deoxydaunomycinone quinone methide reactivity with thiol nucleophiles.

Authors:  K Ramakrishnan; J Fisher
Journal:  J Med Chem       Date:  1986-07       Impact factor: 7.446

10.  Adriamycin and daunomycin induce interstrand DNA crosslinks in Hela S3 Cells.

Authors:  J Konopa
Journal:  Biochem Biophys Res Commun       Date:  1983-02-10       Impact factor: 3.575

View more
  10 in total

1.  An in vitro transcription assay for probing drug-DNA interactions at individual drug sites.

Authors:  D R Phillips; C M Cullinane; D M Crothers
Journal:  Mol Biotechnol       Date:  1998-08       Impact factor: 2.695

2.  Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts.

Authors:  B S Parker; S M Cutts; C Cullinane; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

3.  Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells.

Authors:  C Cullinane; S M Cutts; C Panousis; D R Phillips
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

4.  P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.

Authors:  Tetsuo Yamagishi; Sumit Sahni; Danae M Sharp; Akanksha Arvind; Patric J Jansson; Des R Richardson
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

5.  A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues.

Authors:  Andrew T Lucas; Sara K O'Neal; Charlene M Santos; Taylor F White; William C Zamboni
Journal:  J Pharm Biomed Anal       Date:  2015-11-28       Impact factor: 3.935

6.  Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin.

Authors:  S M Cutts; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-07-11       Impact factor: 16.971

7.  IS METABOLIC ACTIVATION OF TOPOISOMERASE II POISONS IMPORTANT IN THE MECHANISM OF CYTOTOXICITY?

Authors:  Birandra K Sinha; Ronald P Mason
Journal:  J Drug Metab Toxicol       Date:  2015-07-24

8.  Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.

Authors:  B van Hille; X Clerc; A M Creighton; B T Hill
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

9.  Late morfofunctional alterations of the Sertoli cell caused by doxorubicin administered to prepubertal rats.

Authors:  Otávio Brilhante; Fatima K Okada; Estela Sasso-Cerri; Taiza Stumpp; Sandra M Miraglia
Journal:  Reprod Biol Endocrinol       Date:  2012-09-11       Impact factor: 5.211

10.  Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.

Authors:  Kate E Coldwell; Suzanne M Cutts; Ted J Ognibene; Paul T Henderson; Don R Phillips
Journal:  Nucleic Acids Res       Date:  2008-07-16       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.